Bipolar disorder animal model

A non-human animal model for bipolar disorder is created by reducing Teneurin-4 protein expression, replicating manic and depressive phases, facilitating treatment screening and understanding neural mechanisms.

JP7594300B2Active Publication Date: 2024-12-04UNIVERSITY OF TOYAMA
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2021545553
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-09-09
Filing Date
2020-09-08
Publication Date
2024-12-04
Estimated Expiration
2040-09-08

AI Technical Summary

Technical Problem

There is a lack of effective animal models for bipolar disorder, and existing treatments primarily focus on symptomatic relief without addressing the underlying neural circuit abnormalities and neurotransmitter changes associated with the disorder.

Method used

Creating a non-human animal model by reducing Teneurin-4 protein expression in the prefrontal cortex, mimicking manic and depressive phases similar to human bipolar disorder, using methods such as genome editing or lithium administration.

Benefits of technology

The model replicates bipolar disorder symptoms, enabling the development of screening methods for potential treatments and providing insights into neural circuit abnormalities and neurotransmitter changes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007594300000001
    Figure 0007594300000001
  • Figure 0007594300000002
    Figure 0007594300000002
  • Figure 0007594300000003
    Figure 0007594300000003
Patent Text Reader

Abstract

The present invention provides a nonhuman model animal for bipolar disorder, in which the expression of Teneurin-4 protein is reduced in the prefrontal cortex. The present invention also provides a method for creating a nonhuman model animal for bipolar disorder, the method including reducing the expression of Teneurin-4 protein in the prefrontal cortex.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] This patent application claims priority to Japanese Patent Application No. 2019-163646, the entire contents of which are incorporated herein by reference.

[0002] The present application provides an animal model for bipolar disorder. [Background technology]

[0003] Bipolar disorder is a disease in which manic episodes lasting from 15 minutes to 3 hours occur repeatedly during a depressive state. At present, the only pharmacological treatments available are symptomatic treatments, such as administering lithium preparations (the pharmacological mechanism of which has not been elucidated) or sodium valproate (an antiepileptic drug) for manic symptoms, and administering antidepressants for depressive symptoms. In Japan, allopiprazole, a drug used to treat schizophrenia, is used to improve both the manic and depressive symptoms of bipolar disorder, but it is believed that little improvement in the condition can be expected.

[0004] There are many unknowns about abnormalities in the neural circuits and changes in neurotransmitters in bipolar disorder, and no animal models of bipolar disorder exist. A classical animal model has been proposed in which the manic phase is induced by stimulating dopamine receptors and NMDA receptors with stimulants or phencyclidine, and the depressive phase is when the mouse is unable to move due to a lack of dopamine or glutamate, but it is known that this is not consistent with the mechanism of bipolar disorder.

[0005] To date, there are no mouse models of bipolar disorder, and the creation of new models is desired. Summary of the Invention [Problem to be solved by the invention]

[0006] An object of the present application is to provide an animal model for bipolar disorder. [Means for solving the problem]

[0007] The present inventors have found for the first time that by reducing the expression of Teneurin-4 protein in the prefrontal cortex of non-human animals, it is possible to create an animal model that alternates between manic and depressive periods similar to those observed in patients with bipolar disorder.

[0008] In one aspect, the present application provides a non-human animal model of bipolar disorder, in which expression of Teneurin-4 protein is decreased in the prefrontal cortex.

[0009] In another embodiment, there is provided a method for producing a non-human animal model of bipolar disorder, comprising reducing expression of Teneurin-4 protein in the prefrontal cortex. Effect of the Invention

[0010] The present application provides a non-human animal model of bipolar disorder. Furthermore, the method of the present application makes it possible to produce a non-human animal model of bipolar disorder. [Brief description of the drawings]

[0011] [Figure 1A] Western blotting showing decreased Teneurin-4 expression in lithium-exposed SH-SY5Y cells. [Figure 1B] Teneurin-4 expression levels in SH-SY5Y cells exposed to lithium. Values ​​are means ± SEM. n=8; ctrl, n=8; Li2CO3. p=0.000305742. ***p<0.005 vs ctrl (Student t-test). [Figure 1C] Mitochondrial activity in SH-SY5Y cells exposed to lithium. n=10; ctrl, n=10; Li2CO3. p=9.78654E-05. ***p<0.005 vs ctrl (Student t-test).

[0012] [Figure 2A]The gRNA neighboring sequence of the human ODZ4 gene (sequence number 1), the constructed gRNA (sequence number 2), and the vector map of the pGuide-it Vector. [Figure 2B] Results of the cleavage detection assay. [Figure 2C] Results of sequencing analysis.

[0013] [Figure 3A] Western blotting showing decreased expression of Teneurin-4 in SH-SY5Y cells transfected with gRNA-Cas9-GFP vector. [Figure 3B] Teneurin-4 expression levels in SH-SY5Y cells transfected with gRNA-Cas9-GFP vector. Values ​​are means ± SEM. n=5; WT, n=5; gRNA. p=0.001125104. ***p<0.005 vs WT (Student t-test). [Figure 3C] Mitochondrial activity in SH-SY5Y cells transfected with gRNA-Cas9-GFP vector. n=10; WT, n=10; gRNA. p=0.032230494. *p<0.05 vs WT (Student t-test).

[0014] [Figure 4A] Western blotting showing expression of Teneurin-4 protein in each brain region: PFC, prefrontal cortex; NAc, nucleus accumbens; STR, striatum; HIP, hippocampus; OB, olfactory bulb; MB, midbrain; TH, thalamus; CB, cerebellum. [Figure 4B] Expression levels of Teneurin-4 protein in each brain region.

[0015] [Figure 5A] Schematic diagram showing vector injection into the prefrontal cortex (PFC). [Figure 5B]Western blotting showing decreased Teneurin-4 expression in the prefrontal cortex (PFC) in mice injected with gRNA-Cas9-GFP vector into the PFC. [Figure 5C] Expression levels of Teneurin-4 in the prefrontal cortex (PFC) of mice injected with gRNA-Cas9-GFP vector into the PFC.

[0016] [Figure 6] Schedule for each behavioral experiment.

[0017] [Figure 7A] Locomotor activity on day 1 in mice injected with Cas9 virus to reduce Teneurin-4 expression (miTenm4) and mice injected with a control virus (mock). [Figure 7B] Locomotor activity (measurement of behavioral activity) of miTenm4 mice and mock mice on day 2.

[0018] [Figure 8A] Alternation behavior rate in miTenm4 mice and mock mice in the Y-maze test (spontaneous alternation behavior). [Figure 8B] Number of entries by miTenm4 mice and mock mice in the Y-maze test (spontaneous alternation behavior).

[0019] [Figure 9] L / D box test (light / dark box test) in miTenm4 mice and mock mice.

[0020] [Figure 10A] Time spent in the open arms of miTenm4 mice and mock mice in the elevated plus maze test. [Figure 10B]Number of entries into the open arms of miTenm4 mice and mock mice in the elevated plus maze test.

[0021] [Figure 11A] The ratio of approach time to object and stranger mice in miTenm4 mice and mock mice in a three-chamber social interaction test. [Figure 11B] Total approach time of miTenm4 mice and mock mice in a three-chamber social interaction test.

[0022] [Figure 12] Novel object recognition test in miTenm4 and mock mice.

[0023] [Figure 13] Prepulse inhibition test in miTenm4 and mock mice.

[0024] [Figure 14A] Immobility time per minute in miTenm4 mice and mock mice during the forced swimming test. [Figure 14B] Immobility time over a total of 6 min in miTenm4 mice and mock mice in the forced swimming test.

[0025] [Figure 15A] Immobility time per minute in miTenm4 mice and mock mice in the tail suspension test. [Figure 15B]The immobility time over a total of 6 min in miTenm4 mice and mock mice in the tail suspension test.

[0026] [Figure 16] The resting time of miTenm4 mice and mock mice in the environment and tone during the fear conditioning test. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0027] In this disclosure, when a numerical value is accompanied by the term "about," it is intended to include a range of ±10% of that value. For example, "about 20" is intended to include "18-22." A range of numerical values ​​includes all values ​​between and at the endpoints. "About" in reference to a range applies to both endpoints of the range. Thus, for example, "about 20-30" is intended to include "18-33."

[0028] As used herein, "statistically significantly different" or "significantly different" refers to a significant difference between the measured values ​​of a subject and those of a group when the difference between the measured values ​​is statistically processed. "Statistically significant" or "significant" refers to a case where the risk rate (significance level) of the obtained value is small, specifically, p<0.05 (less than 5%), p<0.01 (less than 1%), or p<0.001 (less than 0.1%). Here, "p (value)" indicates the probability that the assumption will be correct by chance in the distribution in which the statistic is assumed in a statistical test. Therefore, the smaller the p value, the closer the assumption is to the truth. The statistical processing test method is not particularly limited, and any known test method capable of determining the presence or absence of significance may be used as appropriate. For example, the Student t-test method and multiple comparison test method can be used.

[0029] 1. Non-human animal models of bipolar disorder In a first aspect, the present application provides a non-human animal model of bipolar disorder in which expression of Teneurin-4 protein in the prefrontal cortex is decreased.

[0030] Teneurin-4 protein is encoded by the ODZ4 gene, which has been reported to have mutations in patients with bipolar disorder through large-scale genomic analysis.

[0031] The amino acid sequence of Teneurin-4 protein and the nucleic acid sequence encoding Teneurin-4 protein are known. For example, the amino acid sequence of Teneurin-4 protein and the nucleic acid sequence encoding Teneurin-4 protein are registered in a database published by the National Center for Biotechnology Information (NCBI).

[0032] The amino acid sequences of Teneurin-4 proteins of mouse, human, chimpanzee, rat and chicken and the accession numbers of the nucleic acid sequences encoding the Teneurin-4 proteins are shown below: Mouse (Mus musculus): NP_001297691 (amino acid sequence), NM_001310762 (nucleic acid sequence); Human (Homo sapiens): NP_001092286 (amino acid sequence), NM_001098816 (nucleic acid sequence); Chimpanzee (Pan troglodytes): XP_016777196 (amino acid sequence), XM_016921707 (nucleic acid sequence); Rat (Rattus norvegicus): NP_001178557 (amino acid sequence), NM_001191628 (nucleic acid sequence); Chicken (Gallus gallus): NP_001341660 (amino acid sequence), NM_001354731 (nucleic acid sequence).

[0033] "Teneurin-4 protein expression is reduced" means that the expression level of Teneurin-4 protein is significantly lower than that of a normal animal of the same species, or an animal of the same species that has not been manipulated to reduce the expression of Teneurin-4 protein. In one embodiment, the expression level of Teneurin-4 protein in the prefrontal cortex of the non-human model animal of bipolar disorder of the present application is reduced to about 10 to about 90%, about 20 to about 80%, about 30 to about 70%, or about 40 to about 60% compared to that of a normal animal of the same species. In another embodiment, the non-human model animal of bipolar disorder of the present application does not express Teneurin-4 in the prefrontal cortex. The expression level of Teneurin-4 protein can be verified by known techniques such as antibody staining and Western blotting. The low expression level of Teneurin-4 protein can also be confirmed by a significantly lower amount of ODZ4 gene or the expression level of ODZ4 gene compared to that of a normal animal of the same species. The amount of the ODZ4 gene or the expression level of the ODZ4 gene can be confirmed by known techniques such as Northern blotting, in situ hybridization, and RT-PCR.

[0034] The non-human animal may be any animal species as long as it is non-human and can be used as an experimental animal, and expresses Teneurin-4 protein. From the viewpoint of using it as a model of human bipolar disorder, it is preferable to use a mammal other than human. Such mammals include primates such as monkeys, rodents, rabbits, cats, dogs, horses, cows, etc. From the viewpoint of easy handling as an experimental animal, rodents such as mice, rats, guinea pigs, hamsters, etc. are preferable, and mice are more preferable.

[0035] 2. Method for producing non-human animal models of bipolar disorder In a second aspect, the present application provides a method for producing a non-human animal model of bipolar disorder, the method comprising reducing expression of Teneurin-4 protein in the prefrontal cortex.

[0036] In some embodiments, decreasing the expression of Teneurin-4 protein in the prefrontal cortex comprises administering to the prefrontal cortex an agent that decreases the expression of Teneurin-4 protein.

[0037] The method for administering a substance that reduces the expression of Teneurin-4 protein to the prefrontal cortex is not particularly limited, but includes, for example, directly injecting a substance that reduces the expression of Teneurin-4 protein into the prefrontal cortex.

[0038] The substance that reduces the expression of Teneurin-4 protein may be, for example, a substance used in genome editing targeting the ODZ4 gene, a substance used in an RNAi method targeting the ODZ4 gene, or a lithium salt.

[0039] The substance used for genome editing targeting ODZ4 gene is not particularly limited, but can be the vector incorporating ZFN, TALEN or CRISPR / Cas9 system, for example, the vector incorporating CRISPR / Cas9 system.In some embodiments, reducing the expression of Teneurin-4 protein in prefrontal cortex comprises administering to prefrontal cortex the vector incorporating the gene encoding Cas9 and the gene encoding gRNA targeting ODZ4 gene.

[0040] The gRNA targeting the ODZ4 gene means a gRNA that can reduce the expression of the ODZ4 gene by the CRISPR / Cas9 system. For example, the gRNA targeting the ODZ4 gene is a gRNA that genetically modifies the ODZ4 gene (substitution, deletion, insertion, etc. of one or more bases) by the CRISPR / Cas9 system so that the Teneurin-4 protein is not expressed. The gRNA targeting the ODZ4 gene can be designed by a known method, and a gRNA design support tool such as CRISPRdirect (https: / / crispr.dbcls.jp / ) may be used.

[0041] The substance used in the RNAi method targeting ODZ4 gene is not particularly limited, but it is ODZ4 gene siRNA or miRNA, or a vector incorporating ODZ4 gene siRNA or miRNA.ODZ4 gene siRNA may be a known one.The application of said siRNA or miRNA includes administering it to the prefrontal cortex as a solution dissolved in a solvent such as physiological saline.

[0042] In the present specification, the vector may be any vector capable of directly introducing a gene into the brain in vivo, and may be a viral vector or a non-viral vector, for example, a viral vector. The viral vector may be an adeno-associated virus (AAV) vector, a lentivirus vector, a herpes virus vector, or the like, for example, an AAV vector. The adeno-associated virus may be adeno-associated virus type 1 (AAV1), adeno-associated virus type 2 (AAV2), adeno-associated virus type 3 (AAV3), adeno-associated virus type 4 (AAV4), or adeno-associated virus type 5 (AAV5). The application of the vector includes administering the vector as a composition containing the vector to the prefrontal cortex. In preparing a composition containing the vector, the vector may be combined with a pharmacokinetically acceptable carrier or vehicle as necessary. A "pharmacokinetically acceptable carrier or vehicle" is a substance that can be administered together with the vector and does not significantly inhibit gene transfer by the vector. The composition containing the vector may be formed, for example, by appropriately diluting the vector with a solvent such as physiological saline. The composition containing the vector may further contain preservatives, suspensions, surfactants, stabilizers, and other additives.

[0043] A known method can be used to incorporate a gene encoding a substance that reduces the expression of Teneurin-4 protein into a vector. Commercially available products may be used, and when incorporating a gene encoding a substance used for genome editing targeting the ODZ4 gene, for example, pGuide-it Vector (Clontech Laboratories) can be used.

[0044] In some embodiments, the substance that reduces the expression of Teneurin-4 protein can be a lithium salt.The lithium salt can be, for example, but not limited to, lithium carbonate, lithium citrate or lithium orotate.The application of lithium salt includes administering it to the prefrontal cortex as a solution dissolved in a solvent such as purified water or physiological saline.

[0045] In another embodiment, reducing the expression of Teneurin-4 protein in prefrontal cortex comprises using known gene modification techniques, such as gene knockout techniques.For example, reducing the expression of Teneurin-4 protein in prefrontal cortex comprises creating the animal that knocks out ODZ4 gene by known gene knockout techniques.

[0046] The fact that a non-human animal model of bipolar disorder has been produced by this method can be confirmed by various known behavioral experiments. The behavioral experiments are not particularly limited, and may be, for example, Locomotor activity (measurement of behavioral amount), Y-maze test (spontaneous alternation behavior), L / D box test (light / dark box test), Elevated plus maze test (elevated plus maze test), Three chamber social interaction test (sociality test), Novel object recognition test (novel object recognition test), Pre pulse inhibition test, Forced swimming test (forced swimming test), Tail suspension test (tail suspension method), and / or Fear conditioning test. Examples of behavioral experiments to examine depressive symptoms include Three chamber social interaction test (sociality test), Forced swimming test (forced swimming test), and Tail suspension test (tail suspension method). Examples of behavioral experiments to examine manic symptoms include Locomotor activity (measurement of behavioral amount). In some embodiments, the non-human animal model of bipolar disorder of the present application exhibits significant differences compared to normal animals of the same species in one, two, three or more of the following behavioral tests: Locomotor activity, Y-maze test, L / D box test, Elevated plus maze test, Three chamber social interaction test, Novel object recognition test, Pre pulse inhibition test, Forced swimming test, Tail suspension test, and Fear conditioning test.In another embodiment, the non-human animal model of bipolar disorder of the present application exhibits a significant difference compared to a normal animal of the same species in at least one behavioral test examining depressive symptoms and at least one behavioral test examining manic symptoms.

[0047] 3. Method for screening substances effective in treating bipolar disorder In a third aspect, the present application provides a method for screening for a substance effective in treating bipolar disorder, characterized by using the non-human model animal of bipolar disorder of the present application or a non-human model animal of bipolar disorder produced by the method of the present application.

[0048] In one embodiment, the screening method of the present application comprises: (1) administering a candidate substance to a non-human animal model of bipolar disorder of the present application or a non-human animal model of bipolar disorder produced by the method of the present application; and (2) evaluating the efficacy of the candidate substance for treating bipolar disorder.

[0049] In the above step (1), a candidate substance is administered to the non-human animal model of bipolar disorder of the present application or a non-human animal model of bipolar disorder produced by the method of the present application. The term "candidate substance" includes any substance, such as a protein, an amino acid, a nucleic acid, a lipid, a carbohydrate, a low molecular weight compound, or an inorganic compound. A candidate substance can typically be used in a purified or isolated form, but may also be an unpurified or unisolated crude product. A candidate substance may be provided in the form of a compound library, a nucleic acid library, a random peptide library, or the like, or may be provided as a natural product.

[0050] The method of administration of the candidate substance is not particularly limited. Examples of administration methods include oral administration, transdermal administration, administration via a mucous membrane, and administration by injection or drip into a vein, an artery, an muscle, a subcutaneous, an intradermal or an intraperitoneal cavity. The administration of the candidate substance can be carried out by an administration form in which the candidate substance is appropriately formulated together with a carrier as necessary.

[0051] In the above step (2), the efficacy of the candidate substance for bipolar disorder is evaluated. In some embodiments, the evaluation of effectiveness can be carried out by various known behavioral experiments, including the above behavioral experiments.For example, in the non-human model animal administered with the candidate substance, if at least one of the results of the above behavioral experiments is improved compared with the control or the non-human model animal before the candidate substance is administered, the candidate substance can be selected as an effective substance for treating bipolar disorder.The control can be, for example, the non-human model animal that is not administered with the candidate substance or the non-human model animal that is administered with an inactive substance.

[0052] As used herein, "treatment" means reducing or eliminating the cause of the disease, slowing or halting the progression of the disease, relieving, alleviating, ameliorating or eliminating its symptoms, and / or inhibiting the worsening of its symptoms. EXAMPLES

[0053] The present invention will be described in more detail below by showing examples, but the present invention is not limited to these examples in any way.

[0054] Reference Example 1. Lithium exposure reduces Teneurin-4 expression and increases mitochondrial activity On day 0, SH-SY5Y cells were cultured at 2.0 × 10 5 cells / well, and 1.9 × 10 for MTT assay 4 On day 1, Li2CO3 solution was added to the medium so that the lithium concentration was 1.0 mEq / L. On days 3 and 5, the medium containing 1.0 mEq / L lithium was replaced with fresh medium. On day 7, the cells were harvested and subjected to Western blotting analysis and MTT assay.

[0055] Western blotting analysis showed that the expression of Teneurin-4 protein was significantly decreased by lithium exposure (Fig. 1A and B), and the MTT assay showed that mitochondrial activity was significantly increased by lithium exposure (Fig. 1C).

[0056] Reference Example 2. Introduction of mutations into ODZ4 DNA using the CRISPR / Cas9 system Using CRISPER direct (https: / / crispr.dbcls.jp / ), 20 bases with high target sequence specificity adjacent to the PAM sequence (NGG) were selected from the ODZ4 DNA sequence, and gRNA (CCCCAAAGAACCGGTTACCG, SEQ ID NO: 2) was designed. The gRNA was inserted into pGuide-it Vector (Clontech Laboratories) to create a gRNA-Cas9-GFP vector. The gRNA adjacent sequence of the targeted human ODZ4 gene, the created gRNA, and the vector map of the pGuide-it Vector are shown in Figure 2A.

[0057] SH-SY5Y cells were transfected with the gRNA-Cas9-GFP vector by electroporation using a Nucleofector (Lonza). Seven days after transfection, gene mutations were detected by sequencing analysis and cleavage detection assay.

[0058] The results of the cleavage detection assay are shown in Figure 2B. The template is a 500bp DNA fragment included with the GeneArt Genomic Cleavage Detection Kit. The control is a cell that was not transfected with the gRNA-Cas9-GFP vector. Only SH-SY5Y cells transfected with the gRNA-Cas9-GFP vector showed two DNA fragments of approximately 300bp and 200bp in size.

[0059] Sequencing analysis confirmed the insertion of a single base into ODZ4 DNA by the CRISPR / Cas9 system (Figure 2C).

[0060] Reference Example 3. Evaluation of mitochondrial activity in SH-SY5Y cells with reduced Teneurin-4 expression On day 0, the gRNA-Cas9-GFP vector was transfected into SH-SY5Y cells by electroporation, and 2.0 × 10 cells were cultured for Western blotting analysis. 5 cells / well, and 8.0 × 10 for MTT assay 4 Cells were seeded at 1000 cells / well. On Day 1 (24 hours after electroporation), the medium was replaced with fresh medium. On Day 3, the cells were harvested and subjected to Western blotting analysis and MTT assay.

[0061] Western blotting analysis showed that Teneurin-4 protein expression was significantly decreased in SH-SY5Y cells transfected with the gRNA-Cas9-GFP vector (Fig. 3A and B). In addition, MTT assay showed that mitochondrial activity was significantly increased in SH-SY5Y cells transfected with the gRNA-Cas9-GFP vector (Fig. 3C).

[0062] Example 1. Expression of Teneurin-4 in various brain regions Mouse brains were divided and dissolved in lysis buffer (10 mM Tris-HCl (pH 7.5) containing 150 mM NaCl, 0.5 mM EDTA, 1% Triton X-100, 0.5% sodium deoxycholate, 0.001% PMSF (phenylmethylsulfonyl fluoride), protease inhibitor cocktail (Nacalai Tesque, Kyoto, Japan), and phosphatase inhibitor cocktail (Nacalai Tesque, Kyoto, Japan)), and suspended in an ultrasonic homogenizer (XL-2000 sonicator (Misonix, Farmingdale, NY)), then centrifuged at 12,000 g. The supernatant was used as the tissue extract. The protein concentration of the samples was quantified by the bicinchoninic acid (BCA) method, and the samples were stored at 4°C. The prepared samples were mixed with sodium dodecyl sulfate (SDS) treatment buffer (250 mM Tris-HCl (pH 6.8) containing 2% SDS, 30% 2-mersaptoethanol, 20% glycerol, and 0.01% bromophenol blue) in a volume ratio of 4:1 and incubated at 4°C overnight, then stored at -30°C until use.

[0063] Next, electrophoresis was performed at room temperature using a 10% polyacrylamide gel. After electrophoresis, the samples were blotted onto a polyvinylidene fluoride (PVDF) membrane (Merck Millipore, Darmstadt, Germany) that had been soaked in 100% methanol for 1 hour at 100 V. After blotting, the samples were blocked for 1 hour in 5% skim milk (dissolved in 20 mM Tris-HCl buffer (TBS-T) (pH 7.5) containing 137 mM NaCl and 0.05% Tween 20), washed with TBS-T, and then reacted with primary antibodies (anti Teneurin-4 from sheep (1 μg / ml, R&D systems, Minneapolis, MN), anti βtubulin from mouse (1 μg / ml MBL, Naka, Japan)) dissolved in TBS-T containing 1% skim milk, and incubated at 4°C overnight. After the reaction, the membrane was washed three times for 10 minutes each with TBS-T, and then reacted with secondary antibodies (anti sheep IgG HRP (1 μg / ml R&D systems), anti mouse IgG HRP (0.5 μg / ml GE Healthcare)) dissolved in TBS-T containing 1% skim milk at room temperature for 1 hour. After washing with TBS-T, the membrane was reacted with a 1:1 mixture of Solution A Luminol Enhancer Solution (GE Healthcare) and Solution B Peroxide Solution (GE Healthcare), and luminescence was observed using an ImageQuant LAS4000mini (GE Healthcare). As a result, it was found that Teneurin-4 was universally expressed in each brain region (Figure 4A and B).

[0064] Example 2. Injection of AAV into mouse prefrontal cortex Seven-week-old male C57BL / 6 mice (SLC Hamamatsu Japan) were anesthetized with a triple-dose anesthesia (Domitor 0.75 mg / kg, Midazolam 4 mg / kg, Vetorfal 5 mg / kg, ip) and fixed in a stereotaxic apparatus. The mice were then injected with Cas9 virus (0.5 μl) or control virus (0.5 μl) to reduce Teneurin-4 expression into the prefrontal cortex (PFC) (AP: +1.8 mm, ML: ±0.3 mm, DV: 1.5 mm, Franklin & Paxinos, The Mouse Brain in Stereotaxic Coordinates 3rd Edition) (Fig. 5A). Four weeks later, the prefrontal cortex (PFC) of each mouse was decapitated and the expression of Teneurin-4 was confirmed by Western blotting to confirm the reduction in expression due to infection. It was confirmed that the expression of Teneurin-4 was significantly decreased at the injection site (Fig. 5B and C).

[0065] Example 3. Various behavioral experiments in mice with decreased Teneurin-4 expression Various behavioral experiments were performed on mice injected with the Cas9 virus (miTenm4) to reduce Teneurin-4 expression and mice injected with a control virus (mock). The schedule for various behavioral experiments is shown in Figure 6. The results are expressed as mean ± standard error. Statistical analysis was performed using the Bonferroni test for multiple comparisons only when significant differences were observed in the unpaired Student's t-test and one-way ANOVA. p < 0.05 was considered to indicate a significant difference. One-way ANOVA was performed using Prism version 5 (GraphPad Software, LaJolla, CA).

[0066] (1) Locomotor activity (measurement of activity amount) Activity was measured as previously reported (Miyamoto et al., Int J. Neuropsychopharmacol 17: 1283-1294. 2014). On the first and second days, mice were allowed to move freely in an acrylic square box (40 × 40 × 30 cm), and activity was measured for a total of 60 minutes at 5-minute intervals using a Scanet MV-40 (Melquest, Toyama, Japan). Activity on the first day is thought to be higher than on the second day because mice show interest in the new environment. Also, the second day is thought to show only locomotion.

[0067] On days 1 (Fig. 7A) and 2 (Fig. 7B), no significant changes in locomotor activity were observed between mice injected with Cas9 virus to reduce Teneurin-4 expression (miTenm4) and mice injected with a control virus (mock) (mock: n=14, miTenm4: n=16) (Fig. 7A and B).

[0068] (2) Y-maze test (spontaneous alternation behavior) The Y-maze test to measure spontaneous alternation behavior was performed as previously reported (Furukawa-Hibi et al., Neurosci Lett. 526:79-84. 2012). Mice were placed at the end of one of the Y-maze arms (40 × 10 × 12 cm), and then allowed to move freely for 8 min. The arms that the mice entered were recorded in order. The number of entries into each arm (total arm entries) and the number of consecutively selecting different arms (number of alternations) were recorded. The alternation behavior rate (%), which is an index, was calculated using the following formula: Alternation behavior rate (%) = [number of alternations / number of entries-2] × 100.

[0069] No significant changes were observed in the alternation rate (FIG. 8A) or number of entries (FIG. 8B) between miTenm4 mice and mock mice (mock: n=14, miTenm4: n=16).

[0070] (3)L / D box test The light / dark box test to measure anxiety-like behavior was performed as previously reported (Fu et al., Sci Rep. 7:13084. 2017). Mice were allowed to move freely for 10 min in a light / dark box consisting of two compartments (15 × 30 × 15 cm), and the time spent in the light and dark boxes was measured using a Scanet MV-40 LD (MELQUEST).

[0071] The time spent in the light box was significantly reduced in miTenm4 mice compared with mock mice (Figure 9) (mock: n=14, miTenm4: n=16).

[0072] (4)Elevated plus maze test The elevated plus-maze to measure anxiety-like behavior was performed as previously reported (Fu et al., Sci Rep. 7:13084. 2017). An elevated plus-maze apparatus was used, consisting of two open arms (25×5×5 cm), two closed arms (25×5×27 cm), and a platform (5×5 cm). The height of the running surface from the floor was 55 cm. Using this apparatus, the time that the mice spent in the open arms was observed for 10 min.

[0073] Compared with mock mice, the time spent in the open arms (FIG. 10A) and the number of entries into the open arms (FIG. 10B) of miTenm4 mice were significantly reduced (mock: n=14, miTenm4: n=16).

[0074] (5) Three chamber social interaction test A three-chambered social interaction test was performed as previously reported (Nadler et al., Genes Brain Behav. 3:303-314. 2004; Nakatani et al., Cell. 137:1235-1246. 2009). An experimental apparatus (60×40×22 cm) made of acrylic and divided into three chambers was used. On the first day, the mice were allowed to move freely in the apparatus for 20 min and then returned to their home cage (habituation). On the second day, a wire cage containing an object was placed in the left chamber and nothing was placed in the other chambers. The mice were placed in the center chamber for 10 min and then allowed to move to the left and right chambers. The mice were allowed to move freely in the three chambers for 10 min and the time it took to approach the wire cage was measured.

[0075] Comparing miTenm4 mice and mock mice, there was no change in the ratio of approach time to the object (Fig. 11A), but the total approach time was significantly decreased in miTenm4 mice (Fig. 11B) (mock: n = 14, miTenm4: n = 16). This indicates that interest in the object in miTenm4 mice is reduced compared to mock mice.

[0076] (6)Novel object recognition test A novel object recognition test to measure cognitive ability was performed as previously reported (Furukawa-Hibi et al., Neurosci Lett. 526:79-84. 2012). For three consecutive days, mice were allowed to explore an acrylic square box (30 × 30 × 35 cm) for 30 minutes per day (habituation). On the fourth day, two objects were placed in the box and the mouse was placed in it. The time and number of times the mouse approached each object were measured for 10 minutes (training). 24 hours after training, one of the objects was replaced with a novel object, and the mouse was placed in the box and the approach time was measured for 10 minutes (trial).

[0077] No significant changes were observed between miTenm4 and mock mice in the novel object recognition test (Figure 12) (mock: n=6, miTenm4: n=8).

[0078] (7)Prepulse inhibition test The PPI test, which measures the auditory startle response and sensory motor control function, was performed based on a previous report (Miyamoto et al., Int J. Neuropsychopharmacol. 20:1027-1035. 2017). The startle response to sound stimuli was measured using the SR-LAB System (San Diego, CA). A 70 dB sound was presented as background noise (BG) in the device. After 10 minutes of acclimation to the 70 dB BG, the startle response test was performed. The startle response test consisted of two stimulation patterns: (i) startle response stimulation (70, 80, 90, 100, 110, 120 dB pulse stimulation, 40 msec) or (ii) PPI stimulation (pulse stimulation (120 dB, 40 msec)), 100 msec before, 20 msec prepulse stimulation of 74, 78, 82, 86 dB was randomly performed 10 times at intervals of 5 to 25 s. At this time, the startle intensity was recorded for 100 msec at 1 msec intervals in synchronization with the pulse stimulation. From the obtained data, PPI was calculated according to the following formula: PPI (%) = 100 - {[mean maximum startle intensity of 120 dB main pulse stimulation - mean maximum startle intensity of (ii) / mean maximum startle intensity of 120 dB main pulse stimulation] × 100.

[0079] In the pre-pulse inhibition test, no significant changes were observed between miTenm4 mice and mock mice (FIG. 13) (mock: n=14, miTenm4: n=16).

[0080] (8) Forced swimming test A forced swimming test to measure depressive-like behavior was performed based on a previous report (Fu et al., Sci Rep. 7:13084. 2017). Mice were placed in a plastic container (21 x 21 x 22.5 cm) containing water (water temperature 25°C) for 6 minutes, and the immobility time per minute was measured using a Scanet MV-40 AQ.

[0081] Compared with mock mice, the immobility time of miTenm4 mice was significantly increased (Fig. 14A and B) (mock: n=13, miTenm4: n=14).

[0082] (9)Tail ​​suspension test The tail suspension test to measure depressive-like behavior was performed based on a previous report (Miyamoto et al., Int J. Neuropsychopharmacol. 20:1027-1035. 2017). Mice were suspended by the tail and immobility time was measured at 1-minute intervals for a total of 10 minutes.

[0083] Compared with mock mice, the immobility time of miTenm4 mice was significantly increased (Fig. 15A and B) (mock: n=13, miTenm4: n=16). .

[0084] (10)Fear conditioning test The contextual fear conditioning test, which measures contextual memory, was performed based on a previous report (Miyamoto et al., Int J. Neuropsychopharmacol. 20:1027-1035. 2017). The mouse was placed in an acrylic box (15 x 15 x 30 cm) with a speaker attached to the ceiling and iron bars on the floor, and allowed to move freely for 2 minutes. After that, a buzzer sound (approximately 100 dB) was played from the speaker for 15 seconds, and during the last 5 seconds, a 0.6 mA current was applied to the iron bars to give the mouse an electrical stimulus (conditioning), which was repeated 4 times at 15-second intervals. The mouse was returned to its home cage and 24 hours later, the mouse was placed in the box again and allowed to move freely for 4 minutes, and the time the mouse was not moving (freezing) was measured.

[0085] Compared with mock mice, miTenm4 mice showed significantly increased immobility time in both environment and tone (mock: n=13, miTenm4: n=16).

Claims

1. A non-human animal model of bipolar disorder in which Teneurin-4 protein expression is reduced exclusively in the prefrontal cortex.

2. The non-human model animal according to claim 1, which is a mouse.

3. A method for producing a non-human animal model of bipolar disorder, comprising reducing expression of Teneurin-4 protein exclusively in the prefrontal cortex.

4. The method of claim 3, wherein reducing the expression of Teneurin-4 protein only in the prefrontal cortex comprises administering to the prefrontal cortex a vector incorporating a gene encoding Cas9 and a gene encoding a guide RNA targeting ODZ4.

5. The method of claim 4, wherein the vector is an adeno-associated virus vector.

6. The method according to any one of claims 3 to 5, wherein the non-human model animal is a mouse.

7. A method for screening for a substance effective in treating bipolar disorder, comprising using the non-human animal model according to claim 1 or 2.

8. The method of claim 7, comprising: (1) administering a candidate substance to the non-human model animal according to claim 1 or 2; and (2) evaluating the efficacy of the candidate substance for treating bipolar disorder.

Citation Information

Patent Citations

  • Methods and compositions for prevention or treatment of a nervous system disorder

    WO2015153760A2